Koen van Rhee
PhD candidate / guest
- Name
- Dr. K.P. van Rhee
- Telephone
- 071 5272727
- k.p.van.rhee@lacdr.leidenuniv.nl
- ORCID iD
- 0000-0001-9195-9783
PhD candidate / guest
- Science
- Leiden Academic Centre for Drug Research
- LACDR/Pharmacology
- Rhee K.P. van (19 February 2025), Unraveling the drivers of antimicrobial pharmacokinetic variability in individuals with obesity and hospitalized patients with multimorbidity (Dissertatie. Leiden Academic Centre for Drug Research (LACDR), Faculty of Science, Leiden University). Supervisor(s) and Co-supervisor(s): Knibbe C.A.J. & Brüggemann R.J.M., Linden P.D. van der .
- Rhee K.P. van, Knibbe C.A.J., Linden P.D. van der & Brüggemann R.J.M. (2024), Patients with obesity should be recognised as a special patient population during drug development of antibacterial and antifungal agents: a Call to Action, Clinical Pharmacokinetics 63: 1-12.
- Rhee K.P. van, Brüggemann R.J.M., Roberts J.A., Sjövall F, Hest R.M. van, Elbers P.W.G., Abdulla A., Linden P.D. van der & Knibbe C.A.J. (2024), Pooled population pharmacokinetic analysis and dose recommendations for ciprofloxacin in intensive care unit patients with obesity, The Journal of Clinical Pharmacology 64(9): 1165-1172.
- Rhee K.P. van, Smit C., Wasmann R.E., Linden P.D. van der, Wiezer R., Dongen E.P. A. van, Krekels E.H.J., Brüggemann R.J.M. & Knibbe C.A.J. (2022), Ciprofloxacin pharmacokinetics after oral and intravenous administration in (morbidly) obese and non-obese individuals: a prospective clinical study, Clinical Pharmacokinetics 61(8): 1167-1175.
- Rhee K.P. van, Vroom S.L. de, Hest R.M. van, Linden P.D. van der, Tonino S.H., Molendijk E., Mathot R.A.A., Blijlevens N.M.A., Knibbe C.A.J., Bruggemann R.J.M. & Geerlings S.E. (2022), Impact of mucositis on oral bioavailability and systemic exposure of ciprofloxacin Gram-negative infection prophylaxis in patients with haematological malignancies, Journal of Antimicrobial Chemotherapy 77(11): 3069-3076.
- Chen L., Rhee K.P. van, Wasmann R.E., Krekels E.H.J., Wiezer M.J., Dongen E.P.A., Verweij P.E., Linden P.D., Bruggemann R.J. & Knibbe C.A.J. (2022), Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults, Journal of Antimicrobial Chemotherapy 77(8): 2217-2226.